Creative Planning’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $502K | Buy |
59,847
+26,303
| +78% | +$220K | ﹤0.01% | 3187 |
|
|
2026
Q1 | $278K | Buy |
33,544
+4,996
| +18% | +$51.7K | ﹤0.01% | 3478 |
|
|
2025
Q4 | $353K | Buy |
28,548
+6,806
| +31% | +$72.9K | ﹤0.01% | 3129 |
|
|
2025
Q3 | $192K | Buy |
21,742
+6,718
| +45% | +$52.3K | ﹤0.01% | 3509 |
|
|
2025
Q2 | $95.9K | Buy |
15,024
+556
| +4% | +$3.18K | ﹤0.01% | 3442 |
|
|
2025
Q1 | $70.3K | Sell |
14,468
-1,532
| -10% | -$12.7K | ﹤0.01% | 3301 |
|
|
2024
Q4 | $153K | Sell |
16,000
-442
| -3% | -$4.06K | ﹤0.01% | 3059 |
|
|
2024
Q3 | $137K | Sell |
16,442
-1,326
| -7% | -$12.1K | ﹤0.01% | 2955 |
|
|
2024
Q2 | $121K | Buy |
17,768
+3,720
| +26% | +$16K | ﹤0.01% | 2803 |
|
|
2024
Q1 | $35.5K | Buy |
+14,048
| New | +$31.7K | ﹤0.01% | 2805 |
|
|
2021
Q3 | – | Sell |
-4,749
| Closed | -$299K | – | 2139 |
|
|
2021
Q2 | $299K | Buy |
4,749
+1,210
| +34% | +$77.7K | ﹤0.01% | 1565 |
|
|
2021
Q1 | $329K | Sell |
3,539
-10,119
| -74% | -$1.04M | ﹤0.01% | 1737 |
|
|
2020
Q4 | $1.22M | Buy |
13,658
+7,833
| +134% | +$719K | ﹤0.01% | 863 |
|
|
2020
Q3 | $602K | Buy |
+5,825
| New | +$628K | ﹤0.01% | 1041 |
|
|
2017
Q3 | – | Sell |
-4,555
| Closed | -$154K | – | 2362 |
|
|
2017
Q2 | $154K | Buy |
4,555
+55
| +1% | +$1.7K | ﹤0.01% | 1669 |
|
|
2017
Q1 | $131K | Hold |
4,500
| – | – | ﹤0.01% | 1776 |
|
|
2016
Q4 | $148K | Sell |
4,500
-5,600
| -55% | -$168K | ﹤0.01% | 1585 |
|
|
2016
Q3 | $318K | Buy |
10,100
+6,000
| +146% | +$174K | ﹤0.01% | 1146 |
|
|
2016
Q2 | $115K | Sell |
4,100
-65
| -2% | -$2.55K | ﹤0.01% | 1578 |
|
|
2016
Q1 | $151K | Sell |
4,165
-35
| -0.8% | -$1.24K | ﹤0.01% | 1371 |
|
|
2015
Q4 | $168K | Sell |
4,200
-18,900
| -82% | -$659K | ﹤0.01% | 1308 |
|
|
2015
Q3 | $658K | Buy |
+23,100
| New | +$761K | 0.01% | 633 |
|
|
2015
Q2 | – | Sell |
-4,200
| Closed | -$121K | – | 1599 |
|
|
2015
Q1 | $121K | Buy |
4,200
+1,534
| +58% | +$44K | ﹤0.01% | 1471 |
|
|
2014
Q4 | $73K | Sell |
2,666
-9,334
| -78% | -$222K | ﹤0.01% | 1736 |
|
|
2014
Q3 | $256K | Buy |
12,000
+11,360
| +1,775% | +$260K | ﹤0.01% | 940 |
|
|
2014
Q2 | $14K | Buy |
640
+350
| +121% | +$8.15K | ﹤0.01% | 2694 |
|
|
2014
Q1 | $7K | Hold |
290
| – | – | ﹤0.01% | 2911 |
|
|
2013
Q4 | $7K | Sell |
290
-200
| -41% | -$4.17K | ﹤0.01% | 2709 |
|
|
2013
Q3 | $9K | Buy |
+490
| New | +$8.75K | ﹤0.01% | 2496 |
|
Other funds holding EBS
OHA
Creative Planning's EBS Position: Q2 2026 in Review
Creative Planning increased its Emergent Biosolutions (EBS) stake by 78% in Q2 2026, buying an estimated $220K and bringing the position to 59,847 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #3187.
Creative Planning first reported a position in EBS in Q3 2013 and has held it in 29 quarters since. The position peaked at $1.22M in Q4 2020. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.
- Creative Planning held 59,847 shares of Emergent Biosolutions worth $502K as of Q2 2026.
- Creative Planning bought 26,303 Emergent Biosolutions shares in Q2 2026, an estimated $220K.
- Emergent Biosolutions made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3187 holding.
- Creative Planning first reported a position in Emergent Biosolutions in Q3 2013 and has held it in 29 quarters since.
- Creative Planning's Emergent Biosolutions position peaked at $1.22M in Q4 2020.
- 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.
Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.